Oscient Pharmaceuticals Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oscient Pharmaceuticals Corporation
Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?
Phillipa Chick, global account director in Intel’s health and life sciences division, laid out the case for decentralizing radiology workflows, and how companies need to educate, rather than convince, bodies like the UK’s NHS in the post-COVID landscape.
Olorofim employs a novel mechanism of action within the antifungal space and was tested in patients with high mortality risk who had exhausted treatment options.